The cell therapy sector is active, and Zhaoyan New Drug hits the daily limit.

MaticHoleFiller · 2026-03-27T21:59:47+00:00

As of March 27th, 14:50, the cell therapy sector performed actively, with Zhaoyan New Drug and Double Goose Pharmaceuticals hitting the daily limit. Stocks such as Tailin Biotech, Hengrui Medicine, and Huahai Pharmaceutical showed significant gains. Investment should be approached with caution.

MaticHoleFiller

2026-03-27 21:59:47

Abstract generation in progress

March 27 news, as of 14:50, the cell therapy sector is active, with Zaiyuan New Drug and Shuanglu Pharmaceutical hitting the daily limit, while Tailin Bio, Hengrui Medicine, and Huahai Pharmaceutical are among the top gainers.

Statement: The market carries risks, and investments should be made cautiously. This article is automatically published based on a third-party database and does not represent Sina Finance’s views. Any information appearing in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcements for discrepancies. For inquiries, please contact biz@staff.sina.com.cn.

A wealth of information and precise interpretations can be found in the Sina Finance APP.

Editor: Xiaolang News Report

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes